“Branded Generics” As A Strategy To Limit Cannibalization Of Pharmaceutical Markets
This paper demonstrates how, by introducing a generic version of its previously-patented product, a branded firm can influence the equilibrium in the generic segment of the market for the product. This in turn can increase the firm’s profits from selling the branded version. We then use structural estimates from previous literature to calculate the magnitude of the effects in the generic and branded segments.
|Date of creation:||May 2005|
|Contact details of provider:|| Postal: 309 Business Bldg., Box 19479, Arlington, Tx 76013|
Phone: (817) 272-3061
Fax: (817) 272-3145
Web page: http://economics.uta.edu/
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Richard G. Frank & David S. Salkever, 1995.
"Generic Entry and the Pricing of Pharmaceuticals,"
NBER Working Papers
5306, National Bureau of Economic Research, Inc.
- Ying Kong & James R. Seldon, 2004. "Pseudo-Generic Products and Barriers to Entry in Pharmaceutical Markets," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 25(1), pages 71-86, 08.
When requesting a correction, please mention this item's handle: RePEc:txa:wpaper:0502. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Shushanik Papanyan)
If references are entirely missing, you can add them using this form.